MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

0.76 1.33

Buy Sell

Overview

Share price change

24h

Current

Min

0.73

Max

0.81

Key metrics
By Trading Economics
Income	-4.5M -52M
Sales	-1.2M 1.9M
EPS	-0.44
Profit margin	-2,803.925
Employees	181
EBITDA	10M -42M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+711.84% upside

Dividends
By Dow Jones
Next Earnings	8 maj 2025

Market Stats
By TradingEconomics
Market Cap	-20M 97M
Previous open	-0.57
Previous close	0.76

News Sentiment

By Acuity

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

0.75 / 0.939899 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 kwi 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 kwi 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 kwi 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 kwi 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 kwi 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 kwi 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 kwi 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 kwi 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 kwi 2025, 22:43 UTC

Top News

Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 kwi 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 kwi 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 kwi 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 kwi 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 kwi 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 kwi 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 kwi 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

711.84% upside

12 Months Forecast

Average 6.17 USD 711.84%

High 12 USD

Low 2.5 USD

Based on 12 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.75 / 0.939899Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

There are no events.

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.